Reddy's launched its generic version of Toprol XL
tablets in the range of 25 mg, 50 mg, 100 mg and 200 mg.
100 and 200 mg and its generic equivalents had total US sales of approximately USD403m (EUR297.
Novartis's Sandoz unit temporarily stopped shipping copies of Toprol XL
during the quarter.
Fitch believes that Watson should also benefit from several recent and upcoming new product opportunities within its existing business, including generic Toprol XL
, the recently launched Gelnique and Rapaflo, and several pending patent challenges with exclusivity such as Mucinex D.
If you used a generic version of AstraZeneca's Toprol XL
in recent years and you found the medications didn't treat your symptoms as effectively as the name brand, you're not alone.
Generic competition to heart drug Toprol XL
in the U.
The court found patents on Toprol XL
( which were due to expire in September 2007 ( were "unenforceable" in a case against rival drugmakers.
As a result, Watson is now eligible for approvals of key generic and branded drugs which had been on regulatory hold, including generic Toprol XL
, Concerta and Cardizem LA as well as the Actos plus metformin extended release branded pharmaceutical.
AstraZeneca Plc's Toprol XL
, given before surgery to prevent heart complications, increases the danger of stroke or death, researchers said.
So far this year, the company has launched a wide range of generics, including versions of AstraZeneca's Toprol XL
, Pfizer Inc.
The generic pipeline now includes Andrx's controlled-release generic projects, including potential first-to-file and semi-exclusive opportunities, most notably generic versions of Toprol XL
, 50mg; Biaxin XL; Concerta; Cardizem LA; Lovenox (with Amphastar); and Prilosec delayed-release.
Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and ability to obtain FDA approval of its Toprol XL
ANDA, whether such ANDA is entitled to the 180-day exclusivity period, and the timing and outcome of litigation related thereto, the Company's dependence on a relatively small number of products, licensing revenues, the timing and outcome of litigation and future product launches generally, its ability to obtain FDA approval of its products, government regulation and changes in the law, competition, and manufacturing results.